Stoke Therapeutics, Inc.
STOK · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $595,718 | $231,413 | $359,023 | $881,375 |
| - Cash | $127,983 | $191,442 | $113,556 | $144,895 |
| + Debt | $4,774 | $2,062 | $2,359 | $1,507 |
| Enterprise Value | $472,509 | $42,033 | $247,826 | $737,987 |
| Revenue | $36,555 | $8,780 | $12,405 | $0 |
| % Growth | 316.3% | -29.2% | – | – |
| Gross Profit | $36,555 | $8,780 | $12,405 | $0 |
| % Margin | 100% | 100% | 100% | – |
| EBITDA | -$99,195 | -$112,304 | -$102,810 | -$85,091 |
| % Margin | -271.4% | -1,279.1% | -828.8% | – |
| Net Income | -$88,981 | -$104,699 | -$101,067 | -$85,805 |
| % Margin | -243.4% | -1,192.5% | -814.7% | – |
| EPS Diluted | -1.65 | -2.38 | -2.6 | -2.34 |
| % Growth | 30.7% | 8.5% | -11.1% | – |
| Operating Cash Flow | -$86,851 | -$81,067 | -$31,866 | -$66,907 |
| Capital Expenditures | -$203 | -$1,616 | -$3,962 | -$1,200 |
| Free Cash Flow | -$87,054 | -$82,683 | -$35,828 | -$68,107 |